Abstract
In the 5 years since the Vioxx debacle, efforts have been made to enhance drug safety. These include the introduction of legislation that expands the power of drug regulatory agencies, new data transparency standards and increased requirements for funding of post-marketing drug surveillance. Nevertheless, some doubt remains that these changes will be sufficient to address the increasing challenges in the field of drug safety. Here, from the perspective of a drug researcher, I discuss key areas for further development that could deliver long-term solutions to these challenges: enhanced tools for the detection of safety signals, innovative phased drug launches, new risk stratification techniques and improved pharmacovigilance operations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Reed, S. D., Anstrom, K. J., Seils, D. M., Califf, R. M. & Schulman, K. A. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Affairs. 27, 360–370 (2008).
Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. FDA web site [online] (2009).
Jones, D. Keeping vigilant about drug safety. Nature Rev. Drug Discov. 6, 855–856 (2007).
Concato, J., Shah, N., Horwitz, R. I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887–1892 (2000).
Breckenridge, A., Woods, K., Raine, J. Monitoring the safety of licensed medicines. Nature Rev. Drug Discov. 4, 541–543 (2005).
The REMS report card: FDA using new tools for one-third of new drugs in first six months. The Pink Sheet (10 Nov 2008).
Food and Drug Administration. Questions and answers on the Federal Register notice on drugs and biological products deemed to have REMS. FDA web site [online] (2007).
Bate, A., Edwards, I. R. Data mining in spontaneous reports. Basic Clin. Pharmacol. Toxicol. 98, 324–330 (2006).
European Medicines Agency. Guideline on the use of statistical signal detection methods in the EudraVigilance data analysis system. EMEA web site [online] (2006).
Baciu, A., Stratton, K. & Burke, S. P. (eds). The Future of Drug Safety: Promoting and Protecting the Health of the Public. (National Academy Press, Washington, 2007).
European Medicines Agency. Guideline on procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to article 14 (8) of regulation (EC) No 726/2004. EMEA web site [online] (2005).
Bouchie, A. Industry reneges on postmarketing trial commitments. Nature Biotech. 21, 718 (2003).
Ray, W. A. & Stein, C. M. Reform of drug regulation, beyond an independent drug safety board. N. Engl. J. Med. 354, 194–201 (2006).
Gale, E. A. M. Lessons from the glitazones: a story of drug development. Lancet 357, 1870–1875 (2001).
Food and Drug Administration. Updated Labeling for Coumadin (Warfarin) (press release). FDA web site [online] (2007).
Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568–579 (2008).
Food and Drug Administration. Information on carbamazepine. FDA web site [online] (2009).
Woodcock, J. & Lesko, L. J. Pharmacogenetics — tailoring treatment for the outliers. N. Engl. J. Med. 360, 811–813 (2009).
European Medicines Agency. Final report on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. EMEA web site [online] (2008).
Carey, J. Improving the use of drugs through genes. BusinessWeek (Washington) (24 Oct 2008).
McKinnon, R. A., Ward, M. B. & Sorich, M. J. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3, 751–759 (2007).
Dow Jones News Service. Accenture and Bristol–Myers Squibb launch pharmaceutical industry's first joint center for pharmacovigilance. Dow Jones Newswire (13 Sept 2007).
Balian, J. D. The next generation pharmacovigilance — establishing collaborative partnerships around the globe to enhance efficiency, flexibility, and patient safety. American Pharmaceutical Outsourcing http://pharmoutsourcing.com/ViewArticle.aspx?SID=qidsz555uxavhrrakt04ga55&ContentID=274 (2008).
Shortell, S. M. & Singer, S. J. Improving patient safety by taking the systems seriously. J. Am. Med. Assoc. 299, 445–447 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A.R. is an employee of Bristol–Myers Squibb.
Related links
Rights and permissions
About this article
Cite this article
Ray, A. Beyond debacle and debate: developing solutions in drug safety. Nat Rev Drug Discov 8, 775–779 (2009). https://doi.org/10.1038/nrd2988
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2988
This article is cited by
-
The determination and interpretation of the therapeutic index in drug development
Nature Reviews Drug Discovery (2012)
-
Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe
Clinical Pharmacology & Therapeutics (2010)
-
Broadening access to electronic healthcare databases
Nature Reviews Drug Discovery (2010)
